CLL Phase 3 Study: Zanubrutinib Bests Ibrutinib CLL Phase 3 Study: Zanubrutinib Bests Ibrutinib
The second-generation Bruton ' s tyrosine kinase inhibitor zanubrutinib outperformed ibrutinib in a phase 3 study in patients with chronic lymphocytic leukemia (CLL) .MDedge News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Hematology | Leukemia | Study